IMMUNOVANT INC (IMVT) Fundamental Analysis & Valuation

NASDAQ:IMVT • US45258J1025

Current stock price

27.03 USD
-0.4 (-1.46%)
Last:

This IMVT fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. IMVT Profitability Analysis

1.1 Basic Checks

  • In the past year IMVT has reported negative net income.
  • IMVT had a negative operating cash flow in the past year.
  • IMVT had negative earnings in each of the past 5 years.
  • In the past 5 years IMVT always reported negative operating cash flow.
IMVT Yearly Net Income VS EBIT VS OCF VS FCFIMVT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 -100M -200M -300M -400M

1.2 Ratios

  • With a Return On Assets value of -44.11%, IMVT perfoms like the industry average, outperforming 52.13% of the companies in the same industry.
  • With a decent Return On Equity value of -47.07%, IMVT is doing good in the industry, outperforming 64.15% of the companies in the same industry.
Industry RankSector Rank
ROA -44.11%
ROE -47.07%
ROIC N/A
ROA(3y)-48.07%
ROA(5y)-40.13%
ROE(3y)-52.89%
ROE(5y)-43.9%
ROIC(3y)N/A
ROIC(5y)N/A
IMVT Yearly ROA, ROE, ROICIMVT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 -20 -40 -60

1.3 Margins

  • IMVT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IMVT Yearly Profit, Operating, Gross MarginsIMVT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. IMVT Health Analysis

2.1 Basic Checks

  • IMVT has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, IMVT has more shares outstanding
  • There is no outstanding debt for IMVT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
IMVT Yearly Shares OutstandingIMVT Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
IMVT Yearly Total Debt VS Total AssetsIMVT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • IMVT has an Altman-Z score of 48.02. This indicates that IMVT is financially healthy and has little risk of bankruptcy at the moment.
  • IMVT has a Altman-Z score of 48.02. This is amongst the best in the industry. IMVT outperforms 95.35% of its industry peers.
  • There is no outstanding debt for IMVT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 48.02
ROIC/WACCN/A
WACCN/A
IMVT Yearly LT Debt VS Equity VS FCFIMVT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M 600M

2.3 Liquidity

  • IMVT has a Current Ratio of 15.74. This indicates that IMVT is financially healthy and has no problem in meeting its short term obligations.
  • IMVT has a Current ratio of 15.74. This is amongst the best in the industry. IMVT outperforms 92.83% of its industry peers.
  • A Quick Ratio of 15.74 indicates that IMVT has no problem at all paying its short term obligations.
  • With an excellent Quick ratio value of 15.74, IMVT belongs to the best of the industry, outperforming 92.83% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 15.74
Quick Ratio 15.74
IMVT Yearly Current Assets VS Current LiabilitesIMVT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. IMVT Growth Analysis

3.1 Past

  • The earnings per share for IMVT have decreased by -2.67% in the last year.
EPS 1Y (TTM)-2.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.74%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, IMVT will show a very strong growth in Earnings Per Share. The EPS will grow by 26.00% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y2.35%
EPS Next 2Y1.07%
EPS Next 3Y1.52%
EPS Next 5Y26%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
IMVT Yearly Revenue VS EstimatesIMVT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 2033 1B 2B 3B
IMVT Yearly EPS VS EstimatesIMVT Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 10 15

More info and screens

Find the best growth stocksShow best growing peers

0

4. IMVT Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for IMVT. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IMVT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IMVT Price Earnings VS Forward Price EarningsIMVT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IMVT Per share dataIMVT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.07%
EPS Next 3Y1.52%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. IMVT Dividend Analysis

5.1 Amount

  • No dividends for IMVT!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

IMVT Fundamentals: All Metrics, Ratios and Statistics

IMMUNOVANT INC

NASDAQ:IMVT (4/16/2026, 9:36:07 AM)

27.03

-0.4 (-1.46%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-06
Earnings (Next)05-27
Inst Owners53.3%
Inst Owner Change0%
Ins Owners1.28%
Ins Owner Change14.52%
Market Cap5.50B
Revenue(TTM)N/A
Net Income(TTM)-464.20M
Analysts82.5
Price Target41.14 (52.2%)
Short Float %21.65%
Short Ratio13.76
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.23%
Min EPS beat(2)0.2%
Max EPS beat(2)16.27%
EPS beat(4)3
Avg EPS beat(4)5.23%
Min EPS beat(4)-7.99%
Max EPS beat(4)16.27%
EPS beat(8)4
Avg EPS beat(8)-3.88%
EPS beat(12)6
Avg EPS beat(12)-3.11%
EPS beat(16)7
Avg EPS beat(16)-3.58%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.88%
PT rev (3m)4.18%
EPS NQ rev (1m)-0.11%
EPS NQ rev (3m)18.19%
EPS NY rev (1m)1.18%
EPS NY rev (3m)10.08%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 5.58
P/tB 5.58
EV/EBITDA N/A
EPS(TTM)-2.69
EYN/A
EPS(NY)-2.68
Fwd EYN/A
FCF(TTM)-2.08
FCFYN/A
OCF(TTM)-2.08
OCFYN/A
SpS0
BVpS4.85
TBVpS4.85
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -44.11%
ROE -47.07%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-48.07%
ROA(5y)-40.13%
ROE(3y)-52.89%
ROE(5y)-43.9%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 47.38%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15.74
Quick Ratio 15.74
Altman-Z 48.02
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)154.15%
Cap/Depr(5y)190.95%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-2.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.74%
EPS Next Y2.35%
EPS Next 2Y1.07%
EPS Next 3Y1.52%
EPS Next 5Y26%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-20.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-9.77%
EBIT Next 3Y-3%
EBIT Next 5YN/A
FCF growth 1Y-101.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-101.18%
OCF growth 3YN/A
OCF growth 5YN/A

IMMUNOVANT INC / IMVT Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for IMMUNOVANT INC?

ChartMill assigns a fundamental rating of 3 / 10 to IMVT.


What is the valuation status of IMMUNOVANT INC (IMVT) stock?

ChartMill assigns a valuation rating of 0 / 10 to IMMUNOVANT INC (IMVT). This can be considered as Overvalued.


How profitable is IMMUNOVANT INC (IMVT) stock?

IMMUNOVANT INC (IMVT) has a profitability rating of 1 / 10.


Can you provide the financial health for IMVT stock?

The financial health rating of IMMUNOVANT INC (IMVT) is 8 / 10.